New Zealand pharma industry calls for faster reimbursement decisions

8 May 2017
new-zealand

The latest annual report from the trade body of New Zealand’s pharmaceutical industry highlights some of the challenges facing the sector.

Medicines New Zealand says, compared with other countries, patients in New Zealand have to wait longer for innovative, cost-effective medicines.

The document highlights the fact that new medicines in New Zealand are typically on a waiting list for over a decade before a decision on reimbursement is reached. For higher priority drugs, the wait time is almost seven years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical